Author: Ravi Shankar

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Disc from this offering are expected to be $450 million, before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 22, 2026, subject to the satisfaction of customary closing conditions.

Disc intends to use the net proceeds from the offering, together with its existing cash, cash equivalents, and marketable securities, to fund research and clinical development of Disc’s current or additional product candidates, to support the potential commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and additional pre-commercialization activities for its other product candidates, and the remainder for working capital and other general corporate purposes.

Jefferies, Leerink Partners, Morgan Stanley and Cantor are acting as joint book-running managers for the offering. LifeSci Capital, BMO Capital Markets and H.C. Wainwright & Co. are acting as co-managers for the offering.

The offering is being made pursuant to an automatic shelf registration statement on Form S-3 (No. 333-281359) that was previously filed with the Securities and Exchange Commission (SEC) on August 8, 2024. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, (800) 808-7525 ext. 6105 or by email at syndicate@leerink.com; Morgan Stanley & Co. LLC, or by email at prospectus@morganstanley.com, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York, 10022, or by email at prospectus@cantor.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Disc Medicine

Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements related to Disc’s expectations regarding the timing and closing of the offering, and the anticipated use of proceeds from the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These risks and uncertainties include fluctuations in Disc’s stock price, changes in market conditions, the satisfaction of customary closing conditions related to the underwritten offering, and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in the prospectus supplement related to the offering we will file with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com

Where Classic Design Meets User Creativity: iCAUR Interprets “Classic Never Fades”

• At the 2026 iCAUR International User Summit, 20 customized vehicles were on display, including three official customization models. The concept design by a Hong Kong winner and the real-vehicle build by a Malaysian designer show how personal interests and regional culture can find expression in a vehicle’s design.
• Building on its classic design language, iCAUR extends personalization across different lifestyles with three official customized models: the V25 Game Changer, V23 Forge, and V27 Sun Roam. All three are slated for launch by early 2027.
• iCAUR has established official user clubs in nine countries and plans to extend its user clubs into more countries through its global Club Connect initiative in 2027. The brand will also set up dedicated areas for personalized customization displays in every showroom, giving user creativity a lasting channel into product and ecosystem development.

WUHU, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — At the 2026 iCAUR International User Summit, iCAUR presented 20 customized vehicles under the theme “Classic Never Fades.” Three of them are official customized models. The display showed how the brand brings together Future Classic Design, new energy technology, and user co-creation to help users express their individuality and make it part of everyday life. User creativity moves from shared ideas to real vehicles, and from there into a user ecosystem rooted in products, culture, and lifestyle. In doing so, iCAUR carries its classic design into the new energy era and brings it through with new life.

[Customization Event at the 2026 iCAUR International User Summit]

Starting with Personal Interests: Design for Different Lifestyles

How can a car bring together people who share the same interests? Wong Po Ying, Open Group champion at the Hong Kong iCAUR V23 AI Design Competition, presented “CYBER PARTY,” a vision for a V23 with a deployable DJ stage and a rear bar counter — a mobile space that blends music, creativity, and outdoor socializing.

Chan Hui Fung Marcus, champion of the Student Group, designed his V23 Omni-X to move between different sides of daily life. In this modular concept, the tailgate turns into a coffee workspace, while the trunk can be fitted with tool drawers and a folding repair bench for bike repairs. Both designs turn personal interests into practical features and open up new ways to expand what a vehicle can do.

Malaysian designer Wang Weiquan brings his hometown into a real vehicle. Daniel Lai Seng Kong, iCAUR’s representative in Malaysia, presented the design on Wang’s behalf: three young people of different ethnicities stand side by side looking into the distance, while details on the roof and body incorporate elements of the local national flag and national flower. Moving from industrial design to graphic design, Wang now looks at how vehicles read visually from different angles. Seeing the design move from screen to the body of a real vehicle left him deeply excited and gave co-creation a tangible outcome.

[Global User Creativity at 2026 iCAUR International User Summit]

Classic Design Sets the Foundation, User Creativity Enriches Official Customization

These user expressions are also the starting point for the brand’s effort to grow customization culture. Ronna, CEO of iCAUR International, said that classic design should be recognized by users today and still appreciated years later, while leaving room for personal expression. In global markets, 50% of iCAUR users customize their vehicles, and their creativity also feeds into product evolution.

[iCAUR V-Series Officially Customized Vehicles and All New V25]

The three official customized vehicles embody this approach. The V25 Game Changer turns game-controller colors and gamepad cues into vehicle details, making digital-life passions visible in the design; the V23 Forge keeps its boxy silhouette, reinforcing its stance with widebody wheel arches, an upright grille, and gloss-black trim; the V27 Sun Roam draws inspiration from 1980s off-road vehicles and vintage cameras, pairing rugged proportions with refined details for those drawn to exploration and well-made journeys. The three models share a classic design foundation, yet each has a personality of its own. They are slated for launch by early 2027, with timing subject to local regulations and market conditions.

Co-creation, On Site and in Local Communities

[Group Photo of Brand Ambassadors]

Keeping creativity flowing into products and daily life requires long-term exchange. iCAUR has established official user clubs in nine countries and plans to extend its user clubs into more countries through the global Club Connect initiative in 2027, with user feedback feeding directly into product and experience improvements. That night, iCAUR named its first brand ambassadors. Going forward, it will continue to recognize, through Club Connect, users who have contributed to the brand and its community.

At the same time, iCAUR plans to set up dedicated display areas for personalized customization in every showroom and showcase customized classic models alongside future new-vehicle launches. Design concepts become real vehicles, and those vehicles spark experience sharing within local communities. Through this, iCAUR keeps users’ creativity flowing into the brand’s evolution — giving “Classic Never Fades” a living meaning.

About iCAUR

Chery Group’s iCAUR is a new energy automotive brand driven by Future Classic Design and technology. Guided by its design philosophy, iCAUR combines classic design elements with modern aesthetics and technology to develop distinctive vehicles for urban mobility and outdoor exploration. With a focus on product innovation and customization, iCAUR offers diverse vehicle choices and personalization options, extending its brand experience through user services and a growing range of user engagements initiatives.

iCAUR’s product portfolio is supported by technologies including i-AWD intelligent electric all-wheel drive and the REEV Golden Range Extender, delivering performance and capability for a range of driving conditions. With a growing presence in more than 40 markets worldwide, iCAUR continues to expand its international business and user engagements, guided by its brand belief: Classic Never Fades.

Serena Wang

Email: wangjieyun2@mychery.com

Website: iCAUR GLOBAL WEB

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/9152b2cd-4fb7-4ba1-86c1-ca4f7abdcd70

https://www.globenewswire.com/NewsRoom/AttachmentNg/4be0ee4a-2704-43fa-b748-10c4594c5d32

https://www.globenewswire.com/NewsRoom/AttachmentNg/4390ca88-ca69-44b8-bdeb-f755c7482065

https://www.globenewswire.com/NewsRoom/AttachmentNg/3f5e8589-51e6-4395-b765-a68401294d5e

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026  and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.

This first-in-class Antibody-Targeted Therapy Conjugate (“ATTC”) drug candidate comprises a highly selective and potent Kirsten rat sarcoma (“KRAS”) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (“EGFR”) antibody. Colorectal, pancreatic and lung cancers have the highest incidence of patients with KRAS-altered tumors, who often lack safe and durable KRAS therapy. HMPL-A830 is designed to address this need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability. The Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors in China and the US was initiated in September 2026 (clinicaltrials.gov identifier NCT07718581).

Under the terms of the agreement, HUTCHMED Limited is responsible for the global Phase I development program. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities in its territory. Following the closing of the exclusive license agreement, HUTCHMED Limited expects to receive US$110 million upfront payment shortly, and may receive additional development, regulatory and commercial milestone payments of up to a total of US$1.185 billion, as well as tiered royalties on annual net sales.

About HUTCHMED ATTCs

HUTCHMED’s ATTCs represent a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action. Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in both efficacy and safety.

Built on over 20 years of targeted therapy expertise, the ATTC platforms enable development of drug candidates across diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve accessibility to tumors and reduce off-tumor toxicity. This may overcome the on-target, off-tumor toxicity limitations of systemically-delivered small molecule inhibitors, which in turn could ensure safer long-term use and support combinations with chemotherapy and immunotherapy in earlier-line treatments.

About KRAS

Rat sarcoma (“RAS”) mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer (“CRC”), 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma (“PDAC”) patients.¹ KRAS regulates key downstream pathways, including RAS/MAPK and PI3K/AKT/mTOR, to drive cell differentiation, proliferation, and survival.

While recent targeted therapies have validated KRAS as a viable therapeutic target, significant clinical gaps persist, particularly for patients with non-G12C mutations. Most patients eventually experience disease progression driven by acquired resistance, largely fueled by upstream receptor tyrosine kinase upregulation and secondary KRAS alterations. Beyond mutation coverage, systemic delivery of pan-KRAS and pan-RAS inhibitors is associated with on-target toxicities, such as dermatological toxicity reflecting RAS pathway inhibition in normal tissue. These present challenges for dosing, long-term tolerability, and combination with cytotoxic chemotherapy or immunotherapy backbones that constitute frontline standard-of-care.

About EGFR

EGFR is a widely expressed receptor tyrosine kinase and established driver of tumor cell proliferation, survival, and disease progression across multiple solid tumors, including CRC, PDAC, and non-small cell lung cancer (“NSCLC”). Signaling through EGFR activates the downstream RAS/MAPK and PI3K/AKT/mTOR pathways, positioning the receptor immediately upstream of KRAS. EGFR has also emerged as a key mediator of resistance to KRAS-targeted therapies, particularly in CRC, where adaptive feedback and increased upstream EGFR signaling reactivate the MAPK pathway and limit the depth and durability of KRAS inhibition. Together, these provide a strong rationale for the dual targeting of EGFR and KRAS, not only in CRC but also additional indications such as PDAC and NSCLC.

About GSK plc

GSK plc is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including, without limitation, statements concerning HUTCHMED’s future plans and prospects, its expectations regarding the therapeutic potential of HMPL-A830 and other drug candidates from the ATTC platform and the further development of HMPL-A830 and other drug candidates from the ATTC platform in this and other indications, as well as the safety, efficacy, tolerability, scalability or combinability of all candidates from the ATTC platform. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the amount and timely receipt of the consideration; the continued sufficiency of preclinical and clinical data to support development and approval of the ATTC-based R&D candidates in China, the United States and other jurisdictions; their potential to gain clinical trial approvals from regulatory authorities; the efficacy and safety profile of HMPL‑A830 and other drug candidates from the ATTC platform; the timing and outcome of clinical studies and the sufficiency of clinical data to support an new drug application submission of HMPL‑A830 and other drug candidates from the ATTC platform in China, the United States or other jurisdictions; its potential to gain approvals from regulatory authorities on an expedited basis or at all; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or the regulatory pathway for the ATTC candidates; HUTCHMED or GSK’s ability to fund, implement and complete its further clinical development and commercialization plans for HMPL‑A830 and other drug candidates from the ATTC platform and the timing of these events. In addition, when or if used herein, the words and phrases “aims,” “anticipates,” “believes,” “continues,” “estimates,” “expects,” “intends,” “may,” “on track,” “predicts,” “plans,” “potential,” “promising,” “should,” “to be,” “will,” and similar expressions and their variants, as they relate to HUTCHMED may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although HUTCHMED believes the expectations reflected in such forward-looking statements are reasonable, HUTCHMED can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in HUTCHMED’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, assumptions regarding the safety, efficacy, supply, continued regulatory approval of these therapeutics, and in some cases connected to the risks of the use of other drug products as combination therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

_________________________________

¹ Singhal A, Li BT & O’Reilly EM. Targeting KRAS in cancer. Nat Med 30, 969–983 (2024). DOI: 10.1038/s41591-024-02903-0

VANCOUVER, BRITISH COLUMBIA, Oct. 20, 2026 (GLOBE NEWSWIRE) — HI-VIEW RESOURCES INC. (“Hi-View” or the “Company”) (CSE: GXLD; OTCQB: GXLDF; FSE: B630) is pleased to announce that its Toodoggone land package, totalling >30,635 hectares, is now 100% owned. The Company has made all the final payments on all its optioned properties, with no further payments outstanding on any property within the package.

R. Nick Horsley, CEO of Hi-View, commented, “We are now in full control of over 30,000 hectares of highly prospective ground in the Toodoggone District. Once all of our assays and data are interpreted, I believe we will have some of the highest-quality porphyry targets in the camp. It has long been our belief that the Toodoggone region will eventually be recognized as one of the richest mineral belts in North America, and Hi-View will directly benefit from its aggressive acquisition strategy and grassroots exploration to date.“

Figure 1. Hi-View Toodoggone Claims
Please click to view image

During the 2026 work program, Hi-View completed 63.78 line-km of induced polarization (IP) surveying, a 250 km² MobileMT survey, 3,251 soil samples, 337 rock samples and approximately 12 km² of geological mapping across ten target areas. Borealis and Lawyers received the largest share of work, with 41.54 line-km of IP and 2,346 soil samples combined. The program was designed to define priority targets and generate new targets for follow-up exploration. Samples have been submitted to ALS Global Laboratory in Vancouver, an ISO/IEC 17025 accredited facility. Assay results will be integrated with the IP and mapping data to rank targets and will be reported once received, reviewed and verified.

As previously announced on August 27, 2025 (see news release here or available on SEDAR+), the Company has issued the final payment of $200,000 and 434,783 common shares to the vendor.

About Hi-View Resources Inc.

Hi-View Resources Inc. is a mineral exploration company listed on the Canadian Securities Exchange. The Company holds a 100% interest in more than 30,635 hectares in the Toodoggone region of northern British Columbia, with no further option payments outstanding on any property. The land package is prospective for gold, silver and copper. Borealis, Lawyers East and Black Pearl are the Company’s priority targets, each with existing anomalies. Additional properties include Golden Stranger, Saunders, Oxide Summit, Nub, Ursus, Garnet, Junkers and Harmon Peak. For more information, visit Hi-View’s website or review the Company’s filings on SEDAR+ (www.sedarplus.ca).

On Behalf of the Board of Directors,

“R. Nick Horsley”
R. Nick Horsley, CEO

For further information, please contact:

Hi-View Resources Inc.
R. Nick Horsley – CEO
Email: info@hiviewresources.com
Telephone: (604) 343-4337
Website: www.hiviewgold.com

FORWARD LOOKING STATEMENTS: 

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.  Forward-looking statements in this news release includes statements related to the Incentive Program and the anticipated use of proceed therefrom. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

WE SEEK SAFE HARBOUR

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

BTDs are granted to innovative drugs or modified new drugs intended for the prevention or treatment of serious, life-threatening diseases or conditions that severely impair quality of life, for which there is no effective treatment, or where sufficient existing evidence demonstrates significant clinical advantages over currently available treatment options. Drug candidates that are granted BTDs receive priority from the CDE for communications and development guidance to accelerate drug development. Furthermore, if the applicant meets the relevant conditions after evaluation, it may apply for Priority Review status and conditional approval when submitting a New Drug Application (NDA) in China. Overall, the BTD pathway is designed to accelerate the development and review of innovative drugs and modified new drugs that offer significant clinical value or address urgent unmet clinical needs.

CLL/SLL is a clonal proliferative malignancy of B lymphocytes that predominantly affects older adults, with more than 100,000 new cases worldwide each year.¹ In recent years, the incidence of CLL/SLL in China has been increasing, with some patients presenting at a younger age and with more aggressive disease.²

In CLL/SLL, immunochemotherapy and BTK inhibitors have been used as first-line treatment options and have achieved favorable response rates and survival outcomes, although certain limitations remain. Immunochemotherapy has limited efficacy in some patients, particularly in those with high-risk features such as del(17p)/TP53 mutations, complex karyotypes, and unmutated IGHV. BTK inhibitor monotherapy, which is an approved standard of care treatment, also has limitations, including insufficient depth of response and concerns regarding long-term safety, and requires continuous treatment. Once treatment fails, patients have very limited subsequent treatment options, with generally poor outcomes. Therefore, there remains an urgent clinical need for fixed-duration combination strategies that improve efficacy and depth of response while reducing adverse events.

Lisaftoclax is a novel, oral, selective Bcl-2 inhibitor developed by Ascentage Pharma. In July 2025, lisaftoclax was approved in China for the treatment of adult patients with CLL/SLL who had previously received at least one systemic therapy including a BTK inhibitor. Lisaftoclax is the first China-developed Bcl-2 inhibitor approved in China and the second Bcl-2 inhibitor approved globally. Ascentage Pharma is currently conducting four global registrational Phase III trials of lisaftoclax. One of these studies, GLORA-2, is a global registrational Phase III trial evaluating the clinical potential of lisaftoclax in combination with acalabrutinib as a first-line treatment for CLL/SLL.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, “This BTD recognizes the clinical potential of Lisaftoclax in combination with acalabrutinib for patients with treatment-naïve CLL/SLL and the urgent unmet need in this setting. Moving forward, we are continuing to accelerate the global clinical development of lisaftoclax across relevant indications and are striving to bring this treatment to more patients as quickly as possible.”

References

1. Yao, Y., Lin, X., Li, F., et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022 Jan 11;21(1):4. DOI: 10.1186/s12938-021-00973-6
2. 刘澎. 复旦大学附属中山医院慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊疗规范（2018）[J].中国临床医学, 2018, 25(1): 157-160. DOI: 10.12015/j. issn.1008-6358.2018.20180

In the United States, lisaftoclax (APG-2575) is an investigational compound and has not been approved by the US FDA. The combination of lisaftoclax and acalabrutinib is investigational and has not been approved in any market.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA- cleared GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:

Ascentage Pharma
IR@ascentage.com
+1 (301) 792-6286

astr partners
brian.korb@astrpartners.com
+1 (917) 653-5122

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Matachewan Consolidated Mines, Limited (TSXV: MCMA) (“Matachewan”) and McChip Resources Inc. (TSXV: MCS) (“McChip” and, together with Matachewan, the “Acquirors”) announce that, on October 19, 2026, they acquired an aggregate of 42,675,809 common shares (the “Common Shares”) of Labrador Gold Corp. (the “Company”) in connection with the closing of the first tranche (the “First Tranche”) of the Company’s non-brokered private placement (the “Offering”). The Company’s head office is located at the Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario M5C 1P1. The address of each of Matachewan and McChip is 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9. 

The First Tranche consisted of the issuance by the Company of 42,675,809 Common Shares on a “flow-through” basis at a price of $0.05 per Common Share, for aggregate gross proceeds of $2,133,790.45. Matachewan acquired ownership of 21,337,905 Common Shares for total consideration of $1,066,895.25, and McChip acquired ownership of 21,337,904 Common Shares for total consideration of $1,066,895.20, in each case at a price of $0.05 per Common Share pursuant to a subscription agreement with the Company. The Common Shares were issued from treasury by way of private placement, and the acquisitions did not take place on any marketplace. 

Immediately prior to closing of the First Tranche, neither Matachewan nor McChip owned or controlled any Common Shares. Immediately following closing of the First Tranche, Matachewan owns and controls 21,337,905 Common Shares and McChip owns and controls 21,337,904 Common Shares, each representing approximately 9.995% of the issued and outstanding Common Shares on a non-diluted basis, an increase of approximately 9.995% for each Acquiror. The Acquirors are joint actors and together own and control 42,675,809 Common Shares, representing approximately 19.99% of the issued and outstanding Common Shares on a non-diluted basis. 

The Acquirors hold their Common Shares as part of a strategic investment in the Company. In connection with the First Tranche, Raymond D. Harari was appointed as a director of the Company and is anticipated to be appointed President at a later date. The Acquirors are entitled to, and intend to, subscribe for additional Common Shares on a non-flow-through basis in the second tranche of the Offering, pursuant to their subscription agreements with the Company and the investor rights agreement among the Company and the Acquirors dated October 19, 2026 (the “Investor Rights Agreement“), such that they collectively hold approximately 19.99% of the issued and outstanding Common Shares following its completion, subject to the cap in the Investor Rights Agreement, TSXV acceptance and applicable law.

Each Acquiror intends to review its holdings in the Company on a continuing basis and may purchase or sell Common Shares in the future, including in private transactions (and, if applicable, through a marketplace), in each case depending on a number of factors. The Acquirors may formulate other purposes, plans or proposals regarding the Company or any of its securities or may change their intentions with respect to any and all matters. The Acquirors, in consultation with the Company, may also propose or seek to effect certain corporate transactions involving the Company. 

The acquisition of the Common Shares did not constitute a formal bid, and the Acquirors did not rely on any exemption from the formal bid requirements in connection with the acquisition. 

Each of Matachewan and McChip will file an early warning report in accordance with applicable securities laws, which will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca. A copy of each early warning report may also be obtained by contacting Zachary Goldenberg, Chief Executive Officer of Matachewan and McChip, at 647-987-5083. 

About Matachewan Consolidated Mines, Limited 

Matachewan is a Canadian natural resource company incorporated in 1933 and headquartered in Toronto, Ontario. Matachewan maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSXV under the symbol MCMA.

About McChip Resources Inc. 

McChip is a Canadian natural resource company incorporated in 1935 and headquartered in Toronto, Ontario. McChip maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSX Venture Exchange under the symbol MCS.

For additional information, please contact: 

Matachewan Consolidated Mines, Limited: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

McChip Resources Inc.: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statements 

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements relating to the Acquirors’ intention to participate in the second tranche of the Offering and their future intentions with respect to their holdings in the Company. Forward-looking information is based on assumptions and is subject to risks and uncertainties, many of which are beyond the control of the Acquirors, that could cause actual results to differ materially, including that the second tranche of the Offering may not be completed on the terms anticipated or at all. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, the Acquirors disclaim any obligation to update or revise any forward-looking information. 

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Matachewan Consolidated Mines, Limited (TSXV: MCMA) (“Matachewan”) and McChip Resources Inc. (TSXV: MCS) (“McChip” and, together with Matachewan, the “Acquirors”) announce that, on October 19, 2026, they acquired an aggregate of 42,675,809 common shares (the “Common Shares”) of Labrador Gold Corp. (the “Company”) in connection with the closing of the first tranche (the “First Tranche”) of the Company’s non-brokered private placement (the “Offering”). The Company’s head office is located at the Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario M5C 1P1. The address of each of Matachewan and McChip is 1 Adelaide Street East, Suite 801, Toronto, Ontario M5C 2V9. 

The First Tranche consisted of the issuance by the Company of 42,675,809 Common Shares on a “flow-through” basis at a price of $0.05 per Common Share, for aggregate gross proceeds of $2,133,790.45. Matachewan acquired ownership of 21,337,905 Common Shares for total consideration of $1,066,895.25, and McChip acquired ownership of 21,337,904 Common Shares for total consideration of $1,066,895.20, in each case at a price of $0.05 per Common Share pursuant to a subscription agreement with the Company. The Common Shares were issued from treasury by way of private placement, and the acquisitions did not take place on any marketplace. 

Immediately prior to closing of the First Tranche, neither Matachewan nor McChip owned or controlled any Common Shares. Immediately following closing of the First Tranche, Matachewan owns and controls 21,337,905 Common Shares and McChip owns and controls 21,337,904 Common Shares, each representing approximately 9.995% of the issued and outstanding Common Shares on a non-diluted basis, an increase of approximately 9.995% for each Acquiror. The Acquirors are joint actors and together own and control 42,675,809 Common Shares, representing approximately 19.99% of the issued and outstanding Common Shares on a non-diluted basis. 

The Acquirors hold their Common Shares as part of a strategic investment in the Company. In connection with the First Tranche, Raymond D. Harari was appointed as a director of the Company and is anticipated to be appointed President at a later date. The Acquirors are entitled to, and intend to, subscribe for additional Common Shares on a non-flow-through basis in the second tranche of the Offering, pursuant to their subscription agreements with the Company and the investor rights agreement among the Company and the Acquirors dated October 19, 2026 (the “Investor Rights Agreement“), such that they collectively hold approximately 19.99% of the issued and outstanding Common Shares following its completion, subject to the cap in the Investor Rights Agreement, TSXV acceptance and applicable law.

Each Acquiror intends to review its holdings in the Company on a continuing basis and may purchase or sell Common Shares in the future, including in private transactions (and, if applicable, through a marketplace), in each case depending on a number of factors. The Acquirors may formulate other purposes, plans or proposals regarding the Company or any of its securities or may change their intentions with respect to any and all matters. The Acquirors, in consultation with the Company, may also propose or seek to effect certain corporate transactions involving the Company. 

The acquisition of the Common Shares did not constitute a formal bid, and the Acquirors did not rely on any exemption from the formal bid requirements in connection with the acquisition. 

Each of Matachewan and McChip will file an early warning report in accordance with applicable securities laws, which will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca. A copy of each early warning report may also be obtained by contacting Zachary Goldenberg, Chief Executive Officer of Matachewan and McChip, at 647-987-5083. 

About Matachewan Consolidated Mines, Limited 

Matachewan is a Canadian natural resource company incorporated in 1933 and headquartered in Toronto, Ontario. Matachewan maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSXV under the symbol MCMA.

About McChip Resources Inc. 

McChip is a Canadian natural resource company incorporated in 1935 and headquartered in Toronto, Ontario. McChip maintains exposure to the natural resource sector through investments in mineral and other resource-related opportunities. Its common shares trade on the TSX Venture Exchange under the symbol MCS.

For additional information, please contact: 

Matachewan Consolidated Mines, Limited: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

McChip Resources Inc.: Zachary Goldenberg, Chief Executive Officer, T: 647-987-5083, E: zach@libertyvp.co

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Forward-Looking Statements 

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements relating to the Acquirors’ intention to participate in the second tranche of the Offering and their future intentions with respect to their holdings in the Company. Forward-looking information is based on assumptions and is subject to risks and uncertainties, many of which are beyond the control of the Acquirors, that could cause actual results to differ materially, including that the second tranche of the Offering may not be completed on the terms anticipated or at all. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable securities laws, the Acquirors disclaim any obligation to update or revise any forward-looking information. 

LAS VEGAS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Galaxy Gaming, Inc. (OTCQX: GLXZ), a leading independent developer and distributor of casino table games and technology, today announced the appointment of John M. Boushy to its Board of Directors, effective October 21, 2026. Mr. Boushy succeeds Meredith Brill, who has informed the Board of her intention to step down after four years of distinguished service, as a Class II Director.

John M. Boushy brings more than 45 years of leadership experience in the gaming, hospitality, technology and entertainment industries. He is the Founder and Managing Member of Boushy Consulting, LLC, where he advises gaming operators, investors and senior executives on strategic, operational and development matters. Through his consulting practice, Mr. Boushy served in executive management roles with the parent company of The Cosmopolitan of Las Vegas, was an advisor to the Second Priority Noteholders Committee during the bankruptcy of Caesars Entertainment Operating Company, served on the board of Caesars Entertainment after its emergence from bankruptcy, and has served since 2015 as Co-Founder and Chairman of the parent company of ReelMetrics.

Prior to founding Boushy Consulting, Mr. Boushy served as Chief Executive Officer, President and Director of Ameristar Casinos, Inc., where he was responsible for leading all aspects of the company’s operations and growth strategy. Before joining Ameristar, he spent more than two decades with Harrah’s Entertainment, Inc., holding a series of senior executive positions including Executive Vice President of Project Development, Design and Construction, Chief Integration Officer, Chief Information Officer, and Senior Vice President of Operations, Marketing and Technology.

During his tenure at Harrah’s, Mr. Boushy oversaw enterprise-wide strategic growth initiatives, enabled by the collaboration of operations, marketing, and information technology; led the integration of the landmark merger between Harrah’s Entertainment and Caesars Entertainment, delivering twice the proforma synergies; and directed major development and capital investment projects. He is widely recognized as an innovator in the application of technology, marketing analytics and operational excellence within the gaming industry, which powers what is now Caesars Total Rewards.

“We are pleased to welcome John to the Galaxy Gaming Board of Directors,” said Mark Lipparelli, Chairman of the Board. “We are fortunate to have someone of his reputation and rare capability lend his expertise to our team. John has been a major force in the gaming industry for several decades, working alongside many of the industry’s most talented leaders and visionaries. He is personally credited with helping advance numerous innovations in gaming operations, marketing and technology throughout his distinguished career. As a senior executive, he has consistently been a demanding partner, a thoughtful collaborator and a catalyst for industry advancement. We look forward to benefiting from his experience, judgment and mentorship in the years ahead.”

Mr. Lipparelli added, “John’s extensive executive leadership experience, coupled with his background in strategic planning, technology innovation, mergers and acquisitions, operations and corporate governance, will be invaluable as Galaxy continues to execute its long-term growth strategy.”

The Board also expressed its appreciation to Meredith Brill for her dedicated service.

“We thank Meredith for her many contributions to Galaxy Gaming over the past four years,” said Mark Lipparelli. “Her insights and guidance have helped position the Company for its next phase of growth, and we wish her every success in her future endeavors.”

About Galaxy Gaming

Headquartered in Las Vegas, Nevada, Galaxy Gaming (galaxygaming.com) develops and distributes innovative games, bonusing systems, and technology solutions to physical and online casinos worldwide. Galaxy Gaming offers games proven to perform developed by gaming experts and backed by the highest level of customer support. Galaxy Gaming Digital is the world’s leading licensor of proprietary table games to the online gaming industry. Galaxy Gaming has 131 licenses worldwide, including licenses in 28 U.S. states.

SAFE HARBOR

This press release contains, and oral statements made from time to time by representatives of Galaxy may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

These forward-looking statements reflect the current views, models, and assumptions of Galaxy, and are subject to various risks and uncertainties that cannot be predicted or qualified and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances, many of which are beyond the control of the Company that may cause actual results in the Company’s performance to differ materially from those expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to risks that the termination of the Merger Agreement disrupts the Company’s current plans and operations or diverts the attention of the Company’s management or employees from ongoing business operations; the risk of potential difficulties with the Company’s ability to retain and hire key personnel and maintain relationships with customers and other third parties as a result of the termination of the Merger Agreement; the risk that the termination of the Merger Agreement may involve unexpected costs and/or unknown or inestimable liabilities; the risk that the Company’s business may suffer as a result of uncertainty surrounding the termination of the Merger Agreement; the risk of stockholder litigation; effects relating to the announcement of the termination of the Merger Agreement on the market price of the Company’s common stock; the ability of Galaxy to enter and maintain strategic alliances, product placements or installations in land based casinos or grow its iGaming business; garner new market share; secure licenses in new jurisdictions or maintain existing licenses; successfully develop or acquire and sell proprietary products; comply with regulations, changes in gaming related and non-gaming related statutes and regulations and/or self-imposed restrictions imposed on and by our customers that affect their revenues in land-based casino and online casino markets; have its games approved by relevant jurisdictions; and adapt to changes resulting from the COVID-19 or other pandemics including without limitation, government imposed shut downs, travel restrictions and supply chain interruptions; and other factors.

Additional information concerning these and other risk factors can be found in the Company’s filings with the Securities and Exchange Commission, including in the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and Definitive Proxy Statement.

All forward-looking statements made herein are expressly qualified in their entirety by these cautionary statements. While forward-looking statements reflect the good faith beliefs of the Company, they are not guarantees of future performance or events, and there can be no assurance that the actual results, events or developments referenced herein will occur or be realized. Readers are cautioned that all forward-looking statements speak only to the facts and circumstances present as of the date of this press release. Galaxy expressly disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, or new information, data or methods, future events or other changes.

Contact:

Media: 
Phylicia Middleton (702) 938-1753 

Investors:         
Steve Kopjo (702) 727-8886

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Q3 2026 Highlights¹

• Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength in underlying demand for Telix’s PSMA products.
• Precision Medicine revenue of US$201 million, increased 30% over the prior corresponding quarter, driven by both Gozellix® and Illuccix®². Telix’s commercial PSMA-PET imaging³ portfolio continued to strengthen its market position, driven by strong demand for our clinically differentiated products.
• U.S. Food and Drug Administration (FDA) approved Pixclara®⁴ for glioma imaging, marking a significant milestone and establishing the first approved imaging agent for this indication in the U.S.⁵. The first commercial doses were administered in September 2026⁶.
• BiPASS®, a Phase 3 study evaluating pre-biopsy prostate cancer detection, completed enrollment⁷, with the FDA supporting an NDA pathway and granting Fast Track Designation⁸.
• Telix announced a merger with Isotope Technologies Munich SE (ITM). The merger creates a leading radiopharmaceutical platform with one of the industry’s broadest therapeutics pipelines, supported by best-in-class isotope production, manufacturing, and supply chain capabilities⁹.
• Telix reaffirmed that FY 2026 revenue and other income is expected to be in excess of US$1 billion, with revenue tracking in line with upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million of other income. The Company has also revised its FY 2026 R&D expenditure guidance range to US$240 million to US$260 million.

Q3 2026 Revenue

Revenue (US$M)	Q3 2026	Q3 2025	% Change	Q2 2026	% Change
Group revenue	245	206	19%	247	(1)%
Precision Medicine revenue10	201	155	30%	202	—%
TMS revenue11	44	47	(6)%	45	(2)%

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality. We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026. We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base. During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry’s broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities. This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale.”

Therapeutics Business Unit

• TLX591-Tx (¹⁷⁷Lu rosopatamab tetraxetan): Following FDA review and alignment of the Part 1 safety data, Telix is finalizing its IND amendment to the FDA to support progression to Part 2 of the ProstACT Global Phase 3 study in the U.S.¹². Outside the U.S., Part 2 of the global study continues to enroll patients across seven countries: Australia, New Zealand, Canada, Türkiye, the UK, Singapore, and South Korea. Regulatory approvals have also been obtained to proceed in China and Japan¹³.
• TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA): OPTIMAL-PSMA¹⁴, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer¹⁵, completed enrollment of 120 patients¹⁶. A data readout is expected in the first half of 2027. OPTIMAL-e¹⁷, a Phase 2 study evaluating TLX597-Tx in metastatic androgen pathway modulator-naive or -sensitive (mAPMN/S) prostate cancer¹⁸, continues to demonstrate strong enrollment momentum.
• TLX250-Tx (¹⁷⁷Lu girentuximab tetraxetan): Continued enrollment of patients in LUTEON¹⁹, a pivotal trial of TLX250-Tx in advanced clear cell Renal Cell Carcinoma (ccRCC). The trial is evaluating the safety and efficacy of TLX250-Tx compared with the investigator’s choice of monotherapy consistent with standard of care.

• TLX101-Tx (iodofalan ¹³¹I): Following full enrollment of the first cohort in Part 1 of the Phase 3 IPAX BrIGHT study²⁰, an IND amendment was filed with the FDA to support expansion of the trial into Part 1b in the U.S. IPAX-2²¹, a Phase 1 study of TLX101-Tx in patients with newly diagnosed glioblastoma met its primary endpoint, establishing a maximum tolerated dose (MTD) of two 5 GBq cycles in combination with standard of care. No dose-limiting toxicities were observed, supporting advancement of IPAX-2 to Phase 2²².

Precision Medicine Business Unit

⁶⁸Ga-PSMA-11 for prostate cancer imaging:

• BiPASS®, a Phase 3 study of ⁶⁸Ga-PSMA-11 PET in combination with MRI for the diagnosis of prostate cancer in the pre-biopsy setting, completed enrollment of 350 patients. Rapid enrollment underscores the unmet need for a minimally invasive option for prostate cancer diagnosis. The study builds on the clinical foundation established by the PRIMARY²³ and PRIMARY2²⁴ studies and is intended to support regulatory submissions. The FDA has supported an NDA pathway that could facilitate reimbursement and granted Fast Track Designation, which may enable an expedited review.
• With enrollment complete in the Phase 3 registrational study of TLX591-Px (Illuccix) in Japan²⁵, Telix is preparing for NDA submission and potential market entry. A Conditional Approval is currently under review by Japan’s Pharmaceutical and Medical Devices Agency (PMDA) and is expected to facilitate an expedited review process.

TLX101-Px (floretyrosine F 18) for brain cancer imaging:

• Telix’s Marketing Authorization Application (MAA) for Pixlumi®²⁶ in Europe remains under review.
• Following the FDA clearance of the IND application, Telix is advancing a Phase 3 registrational study to support expansion of the Pixclara label for the diagnosis of brain metastases.

TLX250-Px, Zircaix®²⁷ (⁸⁹Zr-girentuximab senvedoxam) for kidney cancer imaging:

• Following receipt of the corrected Complete Response Letter (CRL), Telix is finalizing its Biologics License Application (BLA) resubmission package, addressing the remaining third-party manufacturing observations. Resubmission to the FDA is planned in the near term and remains a top priority for the Company in 2026.

Telix Manufacturing Solutions (TMS)

• Through RLS, Telix has established a growing network of micro-pharmacy sites, known as UroOncRx™, providing urologists with onsite access to our imaging agents, particularly in underserved and remote markets. Multiple sites are now operational and dispensing product, further strengthening our radiopharmacy infrastructure and expanding patient access.
• ARTMS, a Telix company, has secured contracts for 50 QUANTM® Irradiation Systems (QIS®) globally, achieving a key commercial milestone and reflecting continued demand for its isotope production technology.
• Telix announced a collaboration with Ekalia²⁸, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, to advance scalable U.S. production of astatine-211 (²¹¹At), an alpha-emitting radioisotope being investigated for targeted alpha therapy. The first IBA alpha-beam cyclotron installation at Telix’s RLS Radiopharmacies site in Trevose near Philadelphia (PA) is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops. The collaboration secures long-term, priority isotope access for Telix’s alpha therapy pipeline, while also supporting third-party academic and industry programs.

Corporate Updates

• Telix announced a transformational merger with ITM, the world’s leading supplier of therapeutic radioisotopes, reinforcing its long-term strategy as a vertically integrated radiopharmaceutical company and further strengthening one of the industry’s broadest therapeutic pipelines. ITM brings a complementary late-stage portfolio led by ITM-11 (¹⁷⁷Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), as well as industry-leading isotope capabilities anchored by the only globally scaled commercial-grade ¹⁷⁷Lu production platform. The transaction includes upfront consideration of US$1.65 billion on a cash-free, debt-free basis, with ITM shareholders expected to receive approximately US$1.25 billion in Telix shares released as ADRs. Additional contingent consideration of up to US$700 million may be paid upon achievement of future regulatory approvals and commercial sales milestones for ITM-11. The transaction remains subject to Telix shareholder approval and customary closing conditions. A General Meeting of Shareholders is expected to be held on December 1, 2026 (AEDT).
• Mr. David Gill was appointed Chair of the Board on September 1, 2026²⁹. Mr. Gill is a life sciences executive with more than 35 years of experience in biopharma, radiopharmaceuticals and medical devices. He has held senior leadership positions, including President, Chief Operating Officer and Chief Financial Officer roles at multiple public companies, and brings extensive expertise in capital markets, governance, business scaling and corporate strategy. He currently serves on the boards of several healthcare companies and holds degrees from Wake Forest University and Emory University.
• Mr. Marcin Firek will join Telix as Company Secretary, effective October 21, 2026. Mr. Firek brings extensive experience in corporate governance, legal affairs, risk management and public company administration, including for dual-listed Australian and U.S. companies. Most recently, he served as Head of Enterprise & Operational Risk at PwC Australia. Previously, he led the Company Secretary team at Woolworths Group Limited, ASX Limited and James Hardie Industries Plc. Earlier in his career, he practiced corporate and M&A law at MinterEllison. Mr. Firek will be the primary person responsible for communications with the ASX under ASX Listing Rule 12.6. Mr. Shomalin Naidoo has also ceased his appointment as interim Company Secretary effective today.

FY 2026 guidance

• Telix expects FY 2026 revenue and other income to exceed US$1 billion, with revenue tracking toward the upper end of its FY 2026 guidance of US$950 million to US$970 million, including US$40 million in other reported income.
• Revenue guidance reflects product sales in markets where marketing authorization has been granted, includes a full-year contribution from RLS, and incorporates anticipated sales of Pixclara.
• Telix revises its FY 2026 R&D expenditure guidance range to US$240 million to US$260 million, previously US$230 million to US$270 million, subject to the achievement of planned clinical, regulatory and development milestones.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. FDA, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan ¹³¹I) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations Annie Kasparian Annie.kasparian@telixpharma.com Charlene Jaw Charlene.jaw@telixpharma.com

Media Eliza Schleifstein Eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

_____________________________________________ 1 The financial information for the quarter ended September 30, 2026 is unaudited. 2 Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Gozellix® (kit for the preparation of gallium-68 gozetotide injection). 3 Imaging of prostate-specific membrane antigen with positron emission tomography. 4 Pixclara® (floretyrosine F 18). 5 Telix ASX disclosure September 14, 2026. 6 Telix press release October 6, 2026. 7 Telix ASX disclosure September 2, 2026. ClinicalTrials.gov ID: NCT07052214. 8 Telix ASX disclosure September 30, 2026. 9 Telix ASX disclosure September 21, 2026. 10 Primarily sales of Illuccix and Gozellix in our Precision Medicine business. 11 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS), excludes Illuccix and Gozellix sales and TMS inter-segment revenue. 12 Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345. 13 Telix ASX disclosure December 17, 2025. 14 Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437. 15 Formerly known as metastatic castration-resistant prostate cancer (mCRPC). 16 Telix LinkedIn June 25, 2026. 17 Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336. 18 Formerly known as metastatic hormone-sensitive prostate cancer (mHSPC). 19 ClinicalTrials.gov ID: NCT07197580. 20 ClinicalTrials.gov ID: NCT07100730. 21 ClinicalTrials.gov ID: NCT05450744 22 Telix media release May 19, 2026. 23 Emmett et al. Eur Urol. 2021. 24 Buteau et al. Lancet Oncol. 2026. ClinicalTrials.gov ID: NCT05154162. 25 Telix media release July 17, 2026. 26 Brand name subject to final regulatory approval. 27 Brand name subject to final regulatory approval. 28 Telix media release October 19, 2026. 29 Telix ASX disclosure September 1, 2026.

Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

20. Oct 2026 / 23:54 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Natural Person

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---